콘텐츠로 건너뛰기
Merck

171824

DL-Proline

99%, for peptide synthesis, ReagentPlus®

동의어(들):

(±)-Pyrrolidine-2-carboxylic acid

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C5H9NO2
CAS 번호:
Molecular Weight:
115.13
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
210-189-3
MDL number:
Beilstein/REAXYS Number:
80812
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


제품 이름

DL-Proline, ReagentPlus®, 99%

Quality Level

product line

ReagentPlus®

assay

99%

form

powder

reaction suitability

reaction type: solution phase peptide synthesis

mp

208 °C (dec.) (lit.)

application(s)

peptide synthesis

SMILES string

OC(=O)C1CCCN1

InChI

1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)

InChI key

ONIBWKKTOPOVIA-UHFFFAOYSA-N

General description

DL-Proline, also known as 2-pyrrolidinylcarboxylic acid, is an amino acid commonly used in solution-phase peptide synthesis due to its ability to act as a turn inducer resulting from its restricted phi( ϕ) angle.

Application

DL-Proline can be is used in the preparation of cis-aminoproline-alkene (cis-Apa)linker, which is further used as an intermediate compound for the synthesis of cyclic pseudopeptides via solution phase peptide synthesis.

Legal Information

ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany


저장 등급

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



Recent Progress in Solid-Phase Total Synthesis of Naturally Occurring Small Peptides
H Yan
Advanced Synthesis & Catalysis, 364, 1934-1961 (2022)
cis-Apa: A practical linker for the microwave-assisted preparation of cyclic pseudopeptides via RCM cyclative cleavage
A Baron
The Journal of Organic Chemistry, 76, 766-772 (2011)
Antoinette Bugyei-Twum et al.
Cardiovascular diabetology, 13, 89-89 (2014-06-03)
Despite advances in the treatment of heart failure, mortality remains high, particularly in individuals with diabetes. Activated transforming growth factor beta (TGF-β) contributes to the pathogenesis of the fibrotic interstitium observed in diabetic cardiomyopathy. We hypothesized that high glucose enhances